Pros and cons of the use of antihistamines in managing allergic rhinitis

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 3 SUPPL., 1999, Pages

  Day, James ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; CETIRIZINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; KININ DERIVATIVE; LEUKOTRIENE; LORATADINE; PROSTAGLANDIN;

ALLERGIC RHINITIS; DRUG CHOICE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG USE; HUMAN; PRIORITY JOURNAL; REVIEW; SOMNOLENCE;

HISTAMINE H1 ANTAGONISTS; HUMANS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 0033054156     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70219-8     Document Type: Article

References (53)

1. Bovet D, Horclois R, Walthert F. Proprietes antihistaminiques de la N-p-methoxybenzyl-N-dimethylaminoethyl α amino-pyridine. C R Soc Biol (Paris) 1944;138:99-100.
2. Douglas WW. Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Goodman AG, Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. 6th ed. New York: Macmillan Publishing Co; 1980. p. 622-3.
3. Bousquet J, Campbell AM, Canonica CW. H1-receptor antagonists: structure and classification. In: Simons FER, editor. Histamine and H1receptor antagonists in allergic disease. New York: Marcel Dekker, Inc; 1996. p. 101-2.
4. Miadonna A, Milazzo N, Lorini M, Marchesi E, Tedeschi A. Antiallergic activity of loratadine: inhibition of leukotriene C4 release from human leukocytes. Clin Exp Allergy 1995;25:364-70.
5. Little MM, Casale TB. Azelastine inhibits Ig-E-mediated human basophil histamine release. J Allergy Clin Immunol 1989;83:862-5.
6. 1-receptor antagonists assessed by nasal challenge. J Allergy Clin Immunol 1988;82:881-7.
7. 1 antihistamine, inhibits histamine release in vivo in the human. Am Rev Respir Dis 1990;142:167-71.
8. 1-antagonists. Clin Exp Allergy 1990;20:3-17.
9. Konno S, Adachi M, Asano K, Matsuo S, Okamoto K, Takahashi T. Inhibitory action of azelastine on cytokine production from human peripheral blood leukocytes in vitro. Life Sci 1993;53:201-6.
10. Rihoux JP, Masliah J, Bereziat G, Konig W. G Proteins as biological targets for anti-allergic drugs? Int Arch Allergy Immunol 1997;113:339-41.
11. 4 production by blood neutrophils in allergic rhinitis: effects of cetirizine. Clin Exp Allergy 1995;25:729-36.
12. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-20.
13. Togias AG, Naclerio RM, Warner J, Proud D, Kagey-Sobotka A, Nimmagadda I, et al. Demonstration of inhibition of mediator release from human mast cells by azatadine base: in vivo and in vitro evaluation. JAMA 1986;255:225-9.
14. Andersson M, Nolte H, Baumgarten C, Pipkorn U. Suppressive effect of loratadine on allergen-induced histamine release in the nose. Allergy 1991;46:540-6.
15. Togias AG, Proud D, Kagey-Sobotka A, Freidhoff L, Lichtenstein LM, Naclerio RM. In vivo and in vitro effects of antihistamines on mast cell mediator release: a potentially important property in the treatment of allergic disease. Ann Allergy 1989;63:465-9.
16. Naclerio RM, Proud D, Kagey-Sobotka A, Freidhoff L, Norman PS, Lichtenstein LM. The effect of cetirizine on early allergic response. Laryngoscope 1989;99:596-9.
17. Shin MH, Baroody F, Proud D, Kagey-Sobotka A, Lichtenstein LM, Naclerio RM. The effect of azelastine on the early allergic response. Clin Exp Allergy 1992;22:289-95.
18. Charlesworth EN, Kagey-Sobokta A, Norman PS, Lichtenstein LM. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 1989;83:905-12.
19. Redier H, Chanez P, De Vos C, Rifai N, Clauzel AM, Michel FB, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992;90:215-24.
20. Ciprandi G, Buscaglia S, Marchesi E, Danzig M, Cuss F, Canonica GW. Protective effect of loratadine on late phase reaction induced by conjunctival provocation test. Int Arch Allergy Immunol 1993;100:185-9.
21. Ciprandi G, Pronzato C, Passalacqua G, Ricca V, Bagnasco M, Grogen J, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996;98:1088-96.
22. Ciprandi G, Pronzato C, Ricca V, Passalacqua G, Danzig M, Canonica GW. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clin Exp Allergy 1997;27:1175-83.
23. 1 antihistamine chlorpheniramine maleate: demonstration of topical effect. Br J Dis Chest 1983;77:113-22.
24. La Force C, Dockhorn RJ, Prenner BM, Chu TJ, Kraemer MJ, Widlitz MD, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol 1996;76:181-8.
25. Storms WW, Pearlman DS, Chervinsky P, Grossman J, Halverson PC, Freitag JJ, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J 1994;73:382-94.
26. Ratner PH, Findlay SR, Hampel F Jr, van Bavel J, Widlitz MD, Freitag JJ. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol 1994;94:818-25.
27. Meltzer EO, Weiler JM, Dockhorn RJ, Widlitz MD, Freitag JJ. Azelastine nasal spray in the management of seasonal allergic rhinitis. Ann Allergy 1994;72:354-9.
28. Weiler JM, Meltzer EO, Bemson PM, Weiler K, Widlitz MD, Freitag J. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol 1994;94:972-80.
29. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998;101:638-45.
30. Baumgarten CR, Petzold U, Dokic D, Aurich R, Kunkel G. Modification of allergen-induced symptoms and mediator release by intranasal azelastine. J Pharmacol U Ther 1994;3:43-51.
31. Brannan MD, Reidenberg P, Radwanski E, Shneyer L, Lin C, Cayen MN, et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electro cardiographic evaluations. Clin Pharmcol Ther 1995;58:269-78.
32. Sale M, Woosley R, Thakker K, Phillips K, Caridi F, Chung M. Effects of cetirizine and erythromycin, alone and in combination on QT interval and pharmacokinetics in healthy subjects [abstract], Ann Allergy Asthma Immunol 1996;76:93.
33. Morganroth J, Lyness W, Perhach JL, Mather GG, Harr JE, Trager WF, et al. Lack of effect of azelastine and ketoconazole coadministration on electro cardiographic parameters in healthy volunteers. J Clin Pharmacol 1997;37:1065-72.
34. Sale M, Lyness W, Perhach J, Woosley R, Rosenberg A. Lack of effect of coadministration of erythromycin with azelastine on pharmaco kinetics or ECG parameters [abstract], Ann Asthma Allergy Immunol 1996;76:91.
35. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-8.
36. Meltzer EO. Antihistamine- and decongestant-induced performance decrements. J Occup Med 1990;32:327-34.
37. Snyder SH, Snowman AM. Receptor effects of cetirizine;. Ann Allergy 1987;59;4-8.
38. Simons FER. H1-receptor antagonists: comparative tolerability and safety. Drug Safety 1994;10:350-80.
39. Betts T, Markman D, Debenham S, Mortiboy D, McKevitt T. Effects of two antihistamine drugs on actual driving performance. BMJ 1984; 288:281-2.
40. Bhatti JZ, Hindmarch I. The effects of terfenadine with and without alcohol on an aspect of car driving performance. Clin Exp Allergy 1989;19:609-11.
41. Gengo FM, Gabos C, Mechtler L. Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator. Ann Allergy 1990;64:520-6.
42. 1-histamine receptor antagonists, astemizole and terfenadine. Br J Clin Pharmacol 1982;199-202.
43. Roth T, Roehrs T, Koshorek G, Sicklesteel J, Zorik F. Sedative effects of antihistamines. J Allergy Clin Immunol 1987;80:94-8.
44. Seidel WF, Cohen S, Bliwise NG, Dement WC. Cetirizine effects on objective measures of daytime sleepiness and performance. Ann Allergy 1987;59:58-62.
45. 1-receptor antagonists. Ann Allergy 1991;66:5-19.
46. Campoli-Richards DM, Buckley MM-T, Fitton A. Cetirizine: a review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma and chronic urticaria. Drugs 1990;40:762-81.
47. Clissold SP, Sorkin EM, Goa KL. Loratadine: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1989;37: 42-57.
48. Falliers CJ, Brandon ML, Buchman E, Connell JT, Dockhorn R, Leese PT, et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991;66:257-62.
49. Vuurman EFPM, van Veggel LMA, Uiterwijk MMC, Leutner D, O'Hanlon JE Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993;71:121-6.
50. Simons FER. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996a;17:185-9.
51. Simons FER, Fraser TG, Reggin JD, Roberts JR, Simons KJ. Adverse central nervous system effects of older antihistamines in children. Pediatr Allergy Immunol 1996b;7:22-7.
52. 1-receptor antagonists) terfenadine and chlorpheniramine in children. J Pediatr 1994;124:979-83.
53. McCue JD. Safety of antihistamines in the treatment of allergic rhinitis in elderly patients. Arch Fam Med 1996;5:464-8.